Edition:
India

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

37.20USD
16 Feb 2018
Change (% chg)

$-1.04 (-2.72%)
Prev Close
$38.24
Open
$38.16
Day's High
$38.55
Day's Low
$36.99
Volume
98,590
Avg. Vol
169,580
52-wk High
$40.62
52-wk Low
$15.97

Chart for

About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,281.57
Shares Outstanding(Mil.): 50.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment

* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY

10 Jan 2018

BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf

* AIMMUNE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2ClRCUj) Further company coverage:

29 Dec 2017

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

06 Nov 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

16 Oct 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

16 Oct 2017

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

16 Oct 2017

Competitors

  Price Chg
DBV Technologies SA (DBV.PA) €41.22 -1.34

Earnings vs. Estimates